GlassScriptPhysician profile
Adebola Orekoya
NPI 1306372735
$2,002.78
in general payments reported to CMS, 2019-2025
11 companies · $1,800 in 2025
The $1,800 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $203 · 2025: $1,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,042 · Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,042.00 |
| Food and Beverage | $960.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,258.21 | 2024-2025 | Onyx Frontier, Hawkone |
| Abiomed | $283.50 | 2024-2025 | Impella |
| Shockwave Medical, INC | $117.10 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $100.61 | 2024-2025 | |
| Amgen INC. | $83.06 | 2024-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $64.21 | 2025 | Amvuttra |
| Philips North America LLC | $26.87 | 2025 | Ineb Devices |
| Lexicon Pharmaceuticals, INC. | $18.92 | 2024 | |
| Ge Healthcare | $17.73 | 2025 | |
| Pfizer INC. | $17.52 | 2024 | |
| Siemens Medical Solutions USA, INC. | $15.05 | 2025 | Acuson Origin Diagnostic Ultrasound System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adebola Orekoya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.